SEC Form 4 · accession 0001125345-18-000044
MACROGENICS INC · MGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Blasius Risser
Officer — Sr VP & Chief Business Officer
Period of report
Mar 2, 2018
Accepted (ET)
Mar 6, 2018 · 5:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001125345
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 2, 2018 | M | 4,000 | $0.94 | A | 13,100 | D | |
| Common StockF2 | Mar 2, 2018 | S | 4,000 | $30.00 | D | 9,100 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F3 | $28.94 | Mar 2, 2018 | A | 70,000 | A | — | Mar 2, 2028 | Common Stock | 70,000 | 70,000 | D |
| Employee stock option (right to buy) | $0.94 | Mar 5, 2018 | M | 4,000 | D | Sep 24, 2009 | Mar 23, 2019 | Common Stock | 4,000 | 21,497 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $30.00 to $30.05.The price reported above reflects the weighted average sale price on the date indicated. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
- F312.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter.